# University Hospital, Rouen: Phase 3 study in Axial or Predominantly Axial SpondyloArthritis With or Without Psoriasis (150 participants)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | University Hospital, Rouen |
| Sponsor type | Academic and hospital |
| Study | Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab |
| NCT ID | NCT07836283 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Axial or Predominantly Axial SpondyloArthritis With or Without Psoriasis |
| Intervention types | drug |
| Target enrollment | 150 |
| Site countries | France |
| Posted | 2026-09-23 |
| Planned start | 2026-10-15 |
| Event | Newly registered study |
| Event date | 2026-09-23 |

## Why this score
- Phase 3: multi-site, larger budget.
- 150 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07836283). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.